Specific phosphorylated tyrosine residues in the kinase insert region of the human platelet-derived-growth-factor /,-receptor mediate the formation of multienzyme complexes with this receptor. When phosphorylated, tyrosine residue 751 within the kinase insert region mediates binding of Ptdlns 3-kinase to this receptor. A 17-amino-acid peptide containing this tyrosine residue was synthesized, phosphorylated by using epidermal-growth-factor receptor and then coupled to an Actigel matrix. The tyrosine-751 phosphopeptide column is used here as a final affinity step in the purification of the Ptdlns 3-kinase from bovine brain to apparent homogeneity. The active resin-bound Ptdlns 3-kinase is composed of two polypeptides, plO and p85, which are elutable with SDS-containing buffers and detectable by silver staining of polyacrylamide gels. The 85 kDa protein is shown to be identical with the recently cloned p85a. Phosphotyrosine is demonstrated to be an essential part of the structure required for binding of both of these proteins and Ptdlns 3-kinase activity to this peptide. The active Ptdlns 3-kinase complex from bovine brain, but not recombinant p85 subunits, shows specificity for binding to phosphopeptides containing a YXXM consensus sequence. Neither Ptdlns 3-kinase activity, nor the complex of p85 and 110 kDa proteins, binds to several other phosphopeptide affinity columns lacking this sequence motif. The selectivity of binding of baculovirus-expressed free p85a subunit of bovine brain Ptdlns 3-kinase, the closely related protein p85,3 and purified bovine brain Ptdlns 3-kinase to these and other phosphopeptide columns is examined.
INTRODUCTION
A subset of polypeptide growth-factor receptors belong to the family of protein-tyrosine kinases. Activation of these receptors following ligand binding involves autophosphorylation of the receptor as well as phosphorylation of a number of intracellular substrate proteins (reviewed in Ullrich & Schlessinger, 1990) . The importance of receptor autophosphorylation had been unclear until recently, when evidence from several laboratories suggested that this event may mediate the formation ofcomplexes between receptor proteins and putative growth-regulatory proteins such as phospholipase Cy (PLCy) (Meisenhelder et al., 1989) , Ptdlns 3-kinase (Coughlin et al., 1989) , GTPase-activating protein (GAP) (Kaplan et al., 1990) ,the serine/threonine kinase Raf and members of the src family of protein-tyrosine kinases (Kypta et al., 1990) (reviewed in Cantley et al., 1991) .
The association of the Ptdlns kinase activity with activated receptors is of particular interest, since increased turnover of Ptdlns and its phosphorylated derivatives has been implicated in the action of hormones, growth factors and transformation of cells by DNA and RNA viruses (reviewed by . Several species of Ptdlns kinase are known to exist, but none of these enzymes have been characterized by cloning and expression. Fibroblasts contain at least two Ptdlns kinase activities, which are distinguishable on the basis of their detergent sensitivity and kinetic properties . These two activities were classified as Type I (inhibited by non-ionic detergents) and Type II (stimulated by non-ionic detergents and inhibited by adenosine). A third distinct species (Type III) has been identified in bovine brain, but remains poorly characterized (Enderman et al., 1987) . One species of Ptdlns kinase activity in particular has become of major interest in the search for second-messenger systems linked to protein-tyrosine kinases, because this activity was shown to co-immunoprecipitate with activated platelet-derived growth factor (PDGF) receptors Coughlin et al., 1989) and with the polyoma middle-T antigen/pp608src (mT: pp60"8rc) complex (Whitman et al., 1985) . This activity has been shown to be due to a Type I Ptdlns kinase which produces novel inositol lipids phosphorylated at the D-3 position of the inositol ring . More recently this enzyme has also been shown to associate with the colony-stimulatingfactor-l receptor (Varticovski et al., 1989) , c-kit receptor (Lev et al., 1991) , the epidermal growth factor (EGF) receptor , the PDGF a-receptor (Yu et al., 1991) , the insulin receptor (Ruderman et al., 1990) , the hepatocyte growth-factor receptor, Met , and with activated nonreceptor protein-tyrosine kinases (Fukui & Hanafusa, 1989; Chan et al., 1990; Varticovski et al., 1991) .
Ptdlns 3-kinase activity has been closely linked to the presence of 81/85 kDa proteins in these immunoprecipitates which can be phosphorylated on tyrosine residues by the associated proteintyrosine kinase both in vitro and in vivo Courtneidge & Heber, 1987; Cohen et al., 1990) . Recently a 650-fold purification of Ptdlns 3-kinase from bovine brain was Vol. 288 Abbreviations used: PDGF, platelet-derived growth factor; EGF, epidermal growth factor; PLC, phospholipase C; GAP, GTPase-activating protein.
1 1 To whom correspondence should be addressed. 383 described which, among other proteins present in the purest preparation, contained an 85 kDa protein which was shown to be a substrate in vitro for the PDGF and EGF receptors (Morgan et al., 1990) . Using sequence information from tryptic peptides derived from this protein we have recently cloned two homologous bovine p85 proteins, denoted p85ac and p85fl (Otsu et al., 1991) . Two other groups have independently cloned murine and human p85cc homologues, using different strategies (Escobedo et al., 1991b; Skolnik et al., 1991) . Both of these p85 proteins can be demonstrated to bind directly to phosphorylated PDGF receptor in vitro (Otsu et al., 1991; Escobedo et al., 1991b) . These proteins may function as the receptor-binding subunits of the Ptdlns 3-kinase, since neither of them can be shown to encode intrinsic Ptdlns 3-kinase activity when expressed in a variety of cell systems (Otsu et al., 1991; Escobedo et al., 1991b) . Immunoprecipitation of 125I-labelled bovine brain Ptdlns 3-kinase with antibodies raised against p85 proteins precipitated an 85 kDa protein together with a second protein of molecular mass 110 kDa (Otsu et al., 1991) . Ptdlns 3-kinase has recently been purified from rat brain and bovine thymus, and in both cases PtdIns 3-kinase activity was associated with the presence of 110 kDa proteins, but not always 85 kDa proteins, strongly suggesting that the 110 kDa component is the catalytic subunit of the active Ptdlns 3-kinase complex ; Shibasaki et al., 1991) .
Ptdlns 3-kinase is one of a growing number of potential signalling proteins which associate with protein-tyrosine kinases activated either by ligand stimulation or as a consequence of cell transformation. A common feature of all these proteins (apart from Raf) is that they contain one or more SH2 domains (src homology) (Koch et al., 1991) . Both p85a and p85/5 proteins contain two SH2 domains. Experiments from a number of laboratories have suggested that these domains may function by binding to peptide sequences phosphorylated on tyrosine residues and thus mediate the complex formation which follows activation of protein-tyrosine kinases Mayer & Hanafusa, 1990; Moran et al., 1990; Matsuda et al., 1991; Mayer et al., 1991 ; reviewed by Koch et al., 1991) . In support of this, several studies suggest that tyrosine phosphorylation of the PDGF receptor or polyoma mT is essential for its association with proteins such as the Ptdlns 3-kinase (Kazlauskas & Cooper, 1989; Talmage et al., 1989) , GAP (Kaplan et al., 1990; and PLCy Margolis et al., 1990 ). The precise tyrosine residue required for binding of the Ptdlns 3-kinase activity (and an 85 kDa phosphoprotein) to the human PDGF receptor has been mapped to tyrosine-751 (Y751), which lies within the kinase insert region of the protein-tyrosine kinase domain (Kazlauskas & Cooper, 1989 Kazlauskas et al., 1991) . The binding sites for other proteins to this receptor (e.g. PLCy, GAP and src-family kinases) have yet to be mapped, but these proteins probably associate via other phosphorylated tyrosine residues.
To define more clearly the polypeptides involved in the active bovine brain Ptdlns 3-kinase complex, we have synthesized peptides from the human PDGF fl-receptor containing either Y751 or Y857, the two major sites of receptor autophosphorylation. These peptides were phosphorylated in vitro by EGF receptor from A43 1 membranes, purified and then coupled to an Actigel matrix. The resulting phosphopeptide columns were then examined for their ability to act as affinity reagents to complete purification of the previously described partially purified bovine brain Ptdlns 3-kinase (Morgan et al., 1990) . A peptide derived from the sequence around tyrosine-751 of the PDGF receptor has proved to be very efficient in binding the bovine brain Ptdlns 3-kinase, making it possible to take the purification to apparent homogeneity. The ability of other SH2-containing proteins, including GAP, PLCy and pp60-8rc, to bind to these and other phosphorylated peptide columns has also been examined. The relevance of the findings to specificity of binding of different SH2-containing proteins is discussed.
MATERIALS AND METHODS

Cells
A431 cells were maintained in Dulbecco's modified Eagle's medium containing 10 % (v/v) foetal-calf serum. Maintenance of insect cell culture and infection of Spodopterafrugiperda (Sf9) cells were carried out as described in Summers & Smith (1987) .
Preparation of A431 membranes
This preparation is modified from that described by Thom et al. (1977 at 2°C to pellet any nuclei/whole cells. Finally, the supernatant was centrifuged at 12000 g for 30 min in a ultracentrifuge SW28 rotor at 4 'C. The membrane pellet was resuspended in a minimum volume of 50 mM-Hepes (pH 7.5), diluted to a final protein concentration of -2 mg/ml and stored at -70 'C.
Synthesis of peptides Synthesis of the peptides described in Table 1 was performed on an Applied Biosystems 430A peptide synthesizer using 9-fluorenylmethoxycarbonyl (FMOC) chemistry and an appropriate amino acid addition program according to Applied Biosystems' recommendations. Peptides were then purified by preparative reverse-phase h.p.l.c. Composition of the peptides was checked by analytical h.p.l.c., amino acid analysis and protein sequencing on a 477A automated pulse-liquid sequencer.
Phosphorylation of peptides
Peptides were freeze-dried to dryness to remove any contaminating chemicals remaining from its synthesis/purification and then dissolved in h.p.l.c.-grade water at a concentration of -4 mg/ml.
For small-scale phosphorylation, we used: 20,tg of peptide, 10 ,tl of 5 x kinase buffer [250 mM-Hepes (pH 7.4), 750 mmNaCl, 0.1 % Triton X-100, 10 mM-MnCl2, 60 mM-MgCl2, 50% Table 1 . Tyrosine-phosphorylation-site synthetic peptides Peptide Sequence For preparative phosphorylation. 2-3 mg of peptide was dissolved in 1.5 ml of water and added to 450 ,u1 of 5 x kinase buffer. The pH was adjusted to 7.0. Then 250 ,u of 0.1 M-ATP and 500 ,u of A431 membranes were added, and the reaction was allowed to proceed for 18 h at room temperature with continual mixing.
Isolation of phosphorylated peptides by reverse-phase h.p.l.c.
A 1 ml portion of buffer A (buffer A: 0.08 % trifluoroacetic acid, 1 % acetonitrile in water; Buffer B: 0.08 % trifluoroacetic acid, 90% acetonitrile) was added to the kinase reaction and mixed. This solution was then spun for 20 min at 10000 g to pellet the membranes. The supernatant containing the phosphopeptide was then loaded on to a Sep-Pak column (C18) equilibrated with buffer A. The column was washed with 20 ml of buffer A to elute ATP and then the peptide was eluted with 3 x I ml of 3:2 mixture of buffers A and B. The A268 of the fractions was monitored, and fractions containing peptide were pooled and then freeze-dried to dryness (note that the phosphorylated Y751 peptide has essentially no absorption at 280 nm). The phosphopeptide was then separated from nonphosphorylated peptide in a 1090 h.p.l.c. system. For preparative separation a C18 column (Aquapore OD-300; 250 mm x 7 mm) equilibrated with 100 % buffer A [214 nm (sensitivity 50 mV)/280 nm (sensitivity 200 mV)] was used with a 2 ml/min flow rate. The peptide was dissolved in 200 ,ul of h.p.l.c.-grade water and then loaded via a 500 #d loop. The column was then washed for 10 min with 100% buffer A before elution of the peptide and phosphopeptide with a 30 min linear gradient from 100 % buffer A to 60 % buffer A/40 % buffer B, followed by a 5 min linear gradient to 100% buffer B. Peak fractions were collected manually. The pool fractions were diluted with water, freeze-dried and then stored at -20 'C.
Phosphoamino acid analysis of phosphorylated peptides
Peptides phosphorylated in the presence of [y-32P]ATP by using either purified EGF receptor or A43 1-cell membranes were purified by h.p.l.c. on a C18 Sep-Pak column as described above. This material was then hydrolysed at 110 'C for 1 h in 1 ml of 6 M-HCl. Then 1 ml of h.p.l.c.-grade water was added and the sample was centrifuged at 10000 g for 10 min to remove debris. The remaining supernatant was frozen and freeze-dried to dryness. The pellet was resuspended in 2 ml of water, frozen and then freeze-dried once more. This material was analysed by twodimensional thin-layer electrophoresis essentially as described by Cooper et al. (1983) .
Coupling of peptides to Actigel resin Peptides were coupled to the matrix essentially as described by the manufacturers. Briefly, 500 1l (packed volume) of Actigel-ALD Superflow resin (Sterogene, Arcadia, CA, U.S.A.) was washed five times with 100 mM-phosphate buffer (pH 7.8) (coupling buffer). Phosphorylated or non-phosphorylated peptide (1 mg) was dissolved in 200 ,ul of coupling buffer and added to the resin. NaCNBH3 (coupling solution) was added to a final concentration of 100 mM, and this was then mixed at 4 'C for 6 h. The resin was washed with 10 column vol. of 500 mM-NaCl and then incubated with 100 mM-Tris/HCl (pH 8.0) for 1 h in the presence of coupling solution to block any sites on the resin that had not reacted. The resin was washed with 500 mM-NaCl and finally with coupling buffer plus 500 ,M-vanadate and 0.02% NaN3 and then stored at 4 'C. Phosphopeptides bound to the Actigel matrix were stable for several months under these conditions.
Binding of proteins to the phosphopeptide columns Proteins were diluted in binding buffer [50 mM-phosphate buffer (pH 7.2), 150 mM-NaCl, 0.02% Triton X-100, 2 mM-EDTA and 200 fSM-sodium orthovanadate], mixed with the appropriate peptide affinity resin and then allowed to bind for 2h at 4 "C with rotation. The column material was washed repeatedly (> 6 times) with 50 column vol. of the same buffer and then with various elution buffers containing NaCl, urea or detergents as described in the text and legends. Bound proteins were either assayed for Ptdlns 3-kinase activity or were removed from the column by boiling in SDS/PAGE sample buffer and then analysed by SDS/PAGE.
Ptdlns 3-kinase assay
Ptdlns 3-kinase assays were carried out essentially as described by Whitman et al. (1987) in 50 ,1 containing 50 mM-Tris/HCl (pH 7.5), 50 mM-NaCl, 1 mM-dithiothreitol, 0.5 mM-EDTA, S mM-MgCl2, 100 ,uM-ATP (plus 0.5 ,uCi of [y-32P]ATP/assay), 1 mM-Ptdlns plus soluble or column-immobilized bovine brain Ptdlns 3-kinase. Incubation was for 5 min at room temperature. Preparation of C-terminal-specffic antisera C-Terminal-peptide-specific antisera were prepared against the bovine C-terminal sequences determined by cDNA cloning (Otsu et al., 1991) . The peptides TLAYPVYAQQRR for p85a and TLAHPVRAPGPGPPPAAR for p85,/ were synthesized by FMOC chemistry and purified by h.p.l.c. The peptides were coupled by using glutaraldehyde to keyhole-limpet haemocyanin and then injected into the lymph nodes of rabbits by methods described in Kypta et al. (1988) . Positive antisera as determined by enzyme-linked immunoassay were affinity-purified on specific peptide-Actigel affinity columns.
RESULTS
Preparation of Y751-phosphopeptide column
A 17-amino-acid peptide which contains Y751 of the human PDGF-fl receptor was chosen for synthesis in an attempt to include all necessary sequence determinants following a survey of the known binding sites for the Ptdlns 3-kinase (see Table 1 ; reviewed by Cantley et al., 1991) . In addition to the peptide context of Y751 of the PDGF ,-receptor, the sequences around Y315 of polyoma middle T (Talmage et al., 1989) and Y721 of the human colony-stimulating-factor-I receptor (Shurtleff et al., 1990) were also considered. With the phosphorylation protocol described here, greater than 50% phosphorylation of the Y751 peptide was achieved by using either purified human EGF receptor or A431 membranes as a source of protein-tyrosine kinase. Fig. 2. Purification of Ptdlns 3-kinase complex on the Y751-phosphopeptide affinity column Modified purification protocol for bovine brain Ptdlns 3-kinase from that previously described by Morgan et al. (1990) . (a) Peak 1 (P1) and peak 2 (P2) of Ptdlns 3-kinase fractions from the second MonoQ step were analysed by SDS/PAGE on a 7.5 % gel. Proteins in these two peak fractions were detected by silver staining. The migration positions of molecular-mass markers are indicated. (b) Affinity purification of peak 1 (P1) and peak 2 (P2) Ptdlns 3-kinase using the Y751-phosphopeptide column. Silver stain after SDS/PAGE of a 7.5 % gel showing PtdIns 3-kinase-associated proteins from MonoQ P1 and P2 which bound to, and were eluted from, the Y75 l-phosphopeptide column with 0.1 %-SDS-containing phosphate buffer at 80 'C. Lanes 1, 2 and 3 for both P1 and P2 material indicates the proteins eluted by successive 50 ul elutions. Phosphoamino acid analysis of the Y75 1 peptide, phosphorylated by either purified EGF receptor or A43 1 membranes, demonstrated that phosphorylation of the Y751 peptide was occurring exclusively at the tyrosine residue (Fig.  1c) . Sequence analysis of the phosphorylated and nonphosphorylated peptides also confirmed that both these peptides were 17 amino acids in length and that their sequences were identical except at cycle 10, where, as expected, no phenylthiohydantoin-tyrosine derivative was observed for the phosphorylated peptide, owing to its modification (results not shown).
Extended purification of bovine brain Ptdlns 3-kinase by using a Y751 phosphopeptide affinity column A 650-fold purification of Ptdlns 3-kinase from bovine brain has recently been described (Morgan et al., 1990) . The material used here was purified by the same method, except that the gradient for the second MonoQ column was extended to give two distinct peaks containing Ptdlns 3-kinase activity ( Fig. 2a ; S. J. Morgan, unpublished work). Both of these peaks (referred to hereafter as peak 1 and peak 2) contain no Ptdlns kinase activity other than Ptdlns 3-kinase activity, as determined by h.p.l.c. analysis of deacylated lipid product (results not shown). However, both of these fractions still contain greater than 20 major polypeptides detectable after SDS/PAGE analysis by silver staining (see Fig. 2a ). The specific activity of peak-l Ptdlns 3-kinase was calculated as 500 nmol/min per mg of protein, and that of peak-2 Ptdlns 3-kinase was 30 nmol/min per mg of protein.
The precise subunit composition of the active Ptdlns 3-kinase complex is still a point of some contention, so an attempt was made to address this question by affinity-purifying the Ptdlns 3-kinase activity from these two MonoQ pools. The bovine brain Ptdlns 3-kinase preparation was diluted 10-fold in binding buffer and allowed to bind batchwise to the Y751-phosphopeptide affinity resin for 4 h at 4 'C. After washing the column extensively with binding buffer, those proteins which remained bound were eluted with SDS-containing buffers and examined by SDS/PAGE. Two major polypeptide species, of approximate molecular masses 85 and 110 kDa (p85 and p 110), which bound specifically to the phosphopeptide column, but not to an identical column prepared with unphosphorylated Y751 peptide, were identified in both MonoQ peaks and were observed to be quantitatively depleted from the bovine brain Ptdlns 3-kinase preparation (Fig. 2b) . Assaying the bound material, we were able to demonstrate that the presence of these two proteins appeared to be sufficient to generate full Ptdlns 3-kinase activity (Fig. 3,  lane 2 ). This Y751-phosphopeptide column routinely removed > 90% of the Ptdlns 3-kinase activity present in the MonoQ peak-I or -2 fractions purified from bovine brain (cf. Fig. 3 , lanes 2 and 3) after a single incubation. Neither the 85 and 110 kDa proteins nor Ptdlns 3-kinase activity bound to a column with an equivalent concentration of non-phosphorylated Y751 peptide (Fig. 3, lane 1) or to a column prepared with phosphotyramine, a phosphotyrosine analogue (results not shown). It should also be noted that binding of the Ptdlns 3-kinase complex to the phosphopeptide column did not result in any apparent increase in the total enzyme activity present (Fig. 3, cf. lanes 2 and 6) . In fact a slight decrease in activity was often observed, but this was judged to be due to the unstable nature of the highly purified enzyme, which was found to be inhibited by traces of metal ions and reversibly inhibited by oxidation (M. J. Fry, unpublished work). It is estimated that this affinity-purification step results in a 7000-8000-fold purification of Ptdlns 3-kinase from bovine brain relative to the material loaded on the DEAE-cellulose (the overall purification achieved from tissue is in fact much greater).
Vol. 288 probed with p85a-specific antiserum, and samples in lanes 3 and 4 were probed with the p85/7-specific antiserum. Lanes 1 and 2: Sf9-cell lysate containing baculovirus-expressed p85a. Lanes 3 and 4: Sf9-cell lysate containing baculovirus-expressed p85/I. In the oddnumbered lanes the nitrocellulose was probed with specific antiserum alone. In the even-numbered lanes the antiserum was competed with 100 j,g of p85a (lane 2) and p85,/ (lane 4) specific C-terminal peptides respectively/ml. (d) Anti-p85a Western blot of bound and soluble Ptdlns 3-kinase material after chromatography using the Y751-phosphopeptide column. Samples (each 1,ug of protein) from peaks 1 (P1) and 2 (P2) of bovine brain PtdIns 3-kinase were immobilized on the Y751-phosphopeptide column. Material which did not bind was collected, and then the resin was washed extensively. Bound proteins were eluted from the column with SDS/PAGE sample buffer. Bound and unbound proteins were separated by SDS/PAGE on a 7.5 % gel and then transferred to nitrocellulose. The filter was then probed with anti-p85a C-terminal antisera and blots were made visible with "25I-Protein A-Sepharose. Lanes: 1, PI bound material; 2, P1 material which did not bind to column; 3, P2 bound material; 4, P2 material which did not bind to column.
Elution of p85, pllO and Ptdlns 3-kinase activity from the phosphopeptide column Elution of the active PtdIns 3-kinase complex from the phosphopeptide column proved to be difficult to achieve, owing . . . . . . . . . . . . . . . . . . . . . . . . . . -. j . , . . to the high affinity of the interaction. have previously noted that the binding of cellular p85 proteins to phosphorylated PDGF receptor was stable to treatment with solutions containing ionic detergents, 2 M-NaCl, 1 Murea or 0.2% SDS. The p85 subunits and Ptdlns 3-kinase complex were also found to bind tightly to the Y751-phosphopeptide matrix and were likewise not eluted under any of the above conditions. At 20°C the 85 and 110 kDa proteins remained bound in the presence of either 2 M-NaCl plus 0.5 % Triton X-100, 5 M-NaCl, 6 M-urea, 50 mM-phosphotyrosine or up to 1 mg of free Y75 1 phosphopeptide/ml. Several alternative elution protocols were investigated without success. An elution medium supplied with the Actigel resin was able to remove both proteins, but led to a complete loss of activity. Interestingly no suitable conditions could be established whereby the 110 kDa, but not the 85 kDa, subunit was released from the column, suggesting that the interaction between the 110 and 85 kDa subunits is also of high affinity. Elution of bound proteins was routinely carried out by heating the resin to 80°C for 3 min in the presence of 5 mM-phosphate buffer (pH 7.0)/0.1 % SDS/0. 1 mM-dithiothreitol/10 % glycerol. The phosphopeptide column could be simply regenerated after elution by extensive washing in binding buffer (Fig. 3, lanes 4 and 5) Fig. 4 shows that these two antisera specifically recognized expressed p85 proteins present in either COS cells or Sf9 cells. Longer exposures also revealed the endogenous COS p85 protein(s), but no such proteins were detected in Sf9 cells with these antisera. No cross-reactivity was observed even at high concentrations of the recombinant proteins, suggesting that they are specific for p85a (Fig. 4a) and p85,/ (Fig. 4b) respectively. The ability of these antisera to interact with the appropriate p85 species was demonstrated to be completely blocked in the presence of the appropriate peptide used to raise the antisera (Fig. 4c) . The p85 species in the two peaks of bovine brain Ptdlns 3-kinase activity which bound to the Y751-phosphopeptide column was found to react exclusively with the anti-C-terminal antisera raised against the p85a-specific sequence (Fig. 4a) . After immobilization of the bovine brain Ptdlns 3-kinase material on the Y751-phosphopeptide column, all the p85a-immunoreactive material was bound to the column, with none detectable by either silver staining or Western-blot analysis in the supernatant (Fig. 4d) .
For sequence analysis of the Ptdlns 3-kinase complex, the 110 and 85 kDa subunits were eluted from the column, after extensive stringent washing, by briefly boiling the resin in 5 mM-phosphate buffer (pH 7.0)/0.1 % SDS/0.1 mM-dithiothreitol/10 % glycerol. Preparation of both the 85 and 110 kDA proteins for digestion with lysyl-endopeptidase and subsequent sequence analysis are described by Totty et al. (1992) . Amino acid sequence analysis of a lysyl-endopeptidase C digest of the p85 protein bound to the Y751-phosphopeptide column was performed. This confirmed that the p85 protein present in both peak 1 and peak 2 from the MonoQ column was identical with the previously cloned p85a (results not shown; Otsu et al., 1991) . No peptides corresponding to p85, were found in either peak. Extensive sequencing of the 110 kDa protein affinity-purified from both MonoQ peak 1 and peak 2 material has led to the isolation of a novel cDNA whose cloning and expression are described elsewhere and pp60c-87c and PLCy purified from bovine brain were used. An identical concentration of BSA or baculovirus-expressed EGF receptor was used as non-specific controls. Both recombinant p85 proteins bound tightly to the phosphorylated, but not the non-phosphorylated, Y751-peptide column. This is shown for p85a in Fig. 5 (lanes 7 and 8) . Neither BSA (Fig. 5, lanes 1 and 2) nor baculovirus-expressed EGF receptor (results not shown) bound to either the phosphorylated or the non-phosphorylated Y751-peptide columns, despite being present at equivalent concentrations to the p85 proteins. Baculovirus-expressed GAP was also found to bind to the Y751-phosphopeptide column (Fig. 5, lane 4) . Neither pp60c8rc from a Sf9-cell lysate (lanes 5 and 6) nor partially purified PLCy (Fig. 5 , lanes 9 and 10) was found to bind to the Y751 control or phosphopeptide columns. In the case ofthe pp60c-8rc this probably reflects a distinct binding-site preference for src-family kinases, as this baculovirus-expressed pp60c-8rc has been shown to be active as a kinase, and is capable of binding to tyrosinephosphorylated PDGF f-receptors and of forming complexes with polyoma middle-T antigen and p85 (Kypta et al., 1990; Otsu et al., 1991; M. J. Fry, unpublished work (Kazlauskas & Cooper, 1989 Kazlauskas et al., 1991) . For a direct comparison with the Y751 peptide, a 17-amino-acid peptide centred around tyrosine-857 was synthesized (see Table 1 ). Fig. 6 shows a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fig. 9 . Binding of PtdIns 3-kinase activity to phosphopeptides containing the YXXM motif (a) A 1 ,cg portion of partially purified peak 1 bovine brain Ptdlns 3-kinase was bound to 10,cul of the indicated peptide columns.
After extensive washing, the columns were assayed for bound Ptdlns 3-kinase activity. Lanes: 1, Ptdlns 3-kinase activity bound to non-phosphorylated Y751 column; 2, Ptdlns 3-kinase activity bound to phosphorylated Y751 column; 3, Ptdlns 3-kinase activity bound to phosphorylated Y751.S column; 4, Ptdlns 3-kinase activity bound to phosphorylated Y857 column; 5, PtdIns 3-kinase activity bound to phosphorylated Y740 column; 6, Ptdlns 3-kinase activity bound to phosphorylated Met Y1313 column. PIP indicates the migration position of a PtdIns4P standard. Ori indicates the origin of the t.l.c. plate. (b) Comparison of identified Ptdlns 3-kinase binding sites in the peptides tested. The proposed consensus sequence for binding is also shown for comparison ).
-P13P -Ori y 5 2 7 Fig. 8 . The p85/P10 complex and Ptdlns 3-kinase activity show specificity in the range of phosphopeptides to which they will bind A 1 ,ug portion of partially purified bovine brain PtdIns 3-kinase (P1 MonoQ) was allowed to bind to peptide affinity columns (defined in Fig. 7) for 4 h at 4°C as described. The columns were then washed repeatedly with binding buffer. Bound proteins were either eluted with SDS-containing buffers and then analysed by SDS/PAGE on 7.50% gels or assayed for Ptdlns 3-kinase activity bound to the column. comparison of the proteins from baculovirus expressing p85a Sf9-cell lysate or from bovine brain Ptdlns 3-kinase fractions from MonoQ peak 1 (P1) and peak 2 (P2) binding to either the Y751 (Fig. 6a) or Y857 (Fig. 6b) phosphopeptide columns. Whereas the baculovirus-expressed p85a is observed to bind to both columns to a similar extent, the 85 and 110 kDa proteins from both peaks of activity are seen only to bind to the Y751-phosphopeptide column. Similarly PtdIns 3-kinase activity is only found associated with the Y751-phosphopeptide column (Fig. 8b) .
To determine whether this binding specificity could be extended, we synthesized several other peptides based on known tyrosine autophosphorylation sites (see Table 1 ). A shorter 11-amino-acid version of the Y75 1 peptide, termed Y75 1 iS, was also synthesized in an attempt to refine further the minimal SH2 recognition domain required. Two other peptides containing the YXXM motif were prepared, one based on the sequence around tyrosine-740 of the PDGF-/? receptor, a second residue within the PDGF-receptor kinase insert which may play a role in PtdIns 3-kinase binding (Escobedo et al., 1991a) , and the second based around tyrosine-1313 of Met, the hepatocyte growth-factor receptor. To introduce a totally random sequence, the synthetic peptide poly(Glu: Ala: Tyr) (6:3:1) was also phosphorylated and coupled to the Actigel matrix. Finally, the peptides surrounding the two major phosphorylation sites from pp6O 8rc, Y416 and Y527, were purchased and synthesized respectively. All peptides were efficiently phosphorylated specifically on tyrosine residues by using the EGF receptor, and then were purified by h.p.l.c. as described above for the Y751 phosphopeptide (results not shown).
Baculovirus-expressed bovine p85a and p85, were chosen to test these columns (Otsu et al., 1991; Gout et al., 1992 Characterization of the Ptdlns 3-kinase complex results not shown). However, when partially purified bovine brain Ptdlns 3-kinase was applied to these columns, it was found to bind exclusively to the phosphopeptide columns containing a YXXM motif (See Figs. 8 and 9a ). The Y740, Y75 1.S and Y1313 phosphopeptide columns containing this YXXM motif all bound bovine brain Ptdlns 3-kinase as efficiently as the original Y751-phosphopeptide column as measured by our assay. No binding of Ptdlns 3-kinase activity was observed with phosphopeptide columns lacking this motif, i.e. Y857, Y416, Y527 or poly(Glu: Ala: Tyr). This result is in agreement with our previous observation that, whereas both cloned p85 species when expressed in a number of cell systems will bind to either phosphorylated PDGF-fl or EGF receptors, the active Ptdlns 3-kinase complex will only bind to the PDGF-,/ receptor under identical conditions (Otsu et al., 1991) . That the Y751.S-phosphopeptide column appears to be as efficient at binding the active Ptdlns 3-kinase complex as the longer Y751-phosphopeptide column suggests that the consensus sequence recently proposed by Cantley et al. (1991) does indeed contain all the sequence data necessary for correct recognition by the Ptdlns 3-kinase SH2 domain (Fig. 9b ).-DISCUSSION Phosphoproteins of 81-85 kDa have been proposed to be important components of the enzyme Ptdlns 3-kinase and were initially thought to be the catalytic subunit (Courtneidge & Heber, 1987; Kaplan et al., 1987) . Partial purification of Ptdlns 3-kinase from bovine brain (Morgan et al., 1990) has allowed the cloning of two closely related 85 kDa bovine brain proteins (termed p85a and p85,8). However, it was shown that these proteins are not sufficient when expressed either alone or together to reconstitute Ptdlns 3-kinase activity (Otsu et al., 1991) . The two cloned p85 proteins in fact appear to be members of a larger gene family containing at least three members which have been fully or partially cloned (Otsu et al., 1991) . Evidence from our own and other laboratories has strongly suggested that the Ptdlns 3-kinase holoenzyme consists of at least two subunits and that a component of 110 kDa might be the catalytic subunit Otsu et al., 1991; Escobedo et at., 1991a,b; Shibasaki et al., 1991) . The studies described here began as an attempt at refinement of the Ptdlns 3-kinase purification described previously by Morgan et al. (1990) . Although it was possible to isolate and sequence an 85 kDa protein from this partial purification, the purest fractions contained a major contaminating protein of 110 kDa , which masked any putative 110 kDa catalytic subunit that might be associated with p85. Since the Ptdlns 3-kinase purification could not be easily improved by using conventional chromatographic methods, presumably owing to the strong protein aggregation, affinity-chromatography techniques were evaluated. Several proteins to which the Ptdlns 3-kinase binds have been well documented, including the PDGF-,8 receptor Coughlin et al., 1989) . The interaction is thought to be mediated between the tyrosine-phosphorylated receptor and the SH2 domain(s) of P85 Otsu et al., 1991; Escobedo et al., 1991a; Skolnik et al., 1991 have been successfully used for affinity purification of these protein-serine kinases (Woodgett, 1989) . The Km values of these kinases for their respective phosphopeptides were in the 5-10 ,IM range. Since the apparent dissociation constant of p85 and the tyrosine-phosphorylated PDGF receptor has been estimated to be below 1 nm (Escobedo et al., 1991b) , it was thought that this interaction might provide the basis for an efficient affinitychromatography step to enhance significantly our previously described purification of the Ptdlns 3-kinase complex from bovine brain (Morgan et al., 1990) .
The initial affinity column prepared, which employed a 17-amino-acid sequence around Y751 of the human PDGF ,-receptor, proved to have a high affinity for the Ptdlns 3-kinase complex, making it possible to remove essentially two proteins from both the peak 1 and peak 2 pool fractions eluted from the last MonoQ column; these were the previously described p85a protein and a protein of approx. 110 kDa. The 85 kDa species present in both peak 1 and peak 2 is identical with that encoded by the p85a cDNA recently cloned by our laboratory and others (Otsu et al., 1991; Escobedo et al., 1991b; Skolnik et al., 1991) .
A p85,8 protein could not be detected in our preparations. The function of p85,/ remains unclear and may mediate distinct receptor-enzyme interactions from that performed by p85a. The 110 kDa protein isolated is novel and probably the same as recently suggested by us (Otsu et al., 1991) , and by others who have purified Ptdlns 3-kinase activity from rat liver , to be the putative catalytic subunit of the Ptdlns 3-kinase complex. This suggestion was strengthened by data from Shibasaki et al. (1991) , who purified two peaks of Ptdlns 3-kinase activity from bovine thymus, one of which was composed of two prominent protein species of 85 and 110 kDa, whereas the other consisted of a single major component of 110 kDa. We have used the-Y751-phosphopeptide affinity column to purify sufficient amounts of the 110 kDa protein for extensive protein sequencing and have now isolated the cDNA for this protein . The reason for the separation of the bovine brain Ptdlns 3-kinase into two distinct peaks of activity on the last MonoQ column is unclear. Possible explanations include the presence of distinct 110 kDa subunits, the covalent modification of one of the two proteins of the PtdIns 3-kinase complex in one of the peaks, or the interaction of Ptdlns 3-kinase with different co-purifying proteins, potentially via SH2-or SH3-mediated interactions. These possibilities require investigation.
It has been proposed that SH2 domains provide a common regulatory mechanism by which enzymically diverse regulatory proteins can physically associate with activated receptors and thereby couple growth-factor stimulation to intracellular signalling pathways (reviewed by Koch et al., 1991) . The data presented here suggest that there is an absolute requirement for tyrosine phosphorylation of these peptide sequences in order for the Ptdlns 3-kinase complex and the 85/110 kDa proteins to bind. Moreover, our preliminary results (not shown) obtained using the Pharmacia BlAcore biosensor to measure binding constants for both SH2-domain-containing proteins and isolated SH2 domains to various phosphorylated and non-phosphorylated peptides support the observation that phosphorylation of the peptide is essential for binding.
No increase in Ptdlns 3-kinase activity was observed upon binding to any of the phosphopeptide columns described in this paper. This point is worthy of note, because the precise mechanism for the activation of the Ptdlns 3-kinase after ligand stimulation of a receptor is currently an area of intense speculation. It is not clear whether the translocation of the Ptdlns 3-kinase from the cytosol to a membrane-associated location after its binding to an autophosphorylated receptor, thus bringing it into close proximity to its substrates, is sufficient for activation, Vol. 288 391 or whether subsequent events are also required. It has also been suggested that binding to an autophosphorylated receptor might induce an activating conformational change in the Ptdlns 3-kinase or that tyrosine phosphorylation by the receptor might also activate this enzyme (reviewed by Cantley et al., 1991) . The experiment described here dissociates the binding of the Ptdlns 3-kinase complex to a tyrosine-phosphorylated receptor sequence from the subsequent phosphorylation of the Ptdlns 3-kinase subunits by the receptor and suggests that binding to the activated tyrosine-phosphorylated receptor alone is probably not sufficient to induce a change in Ptdlns 3-kinase activity. The events required for Ptdlns 3-kinase activation remains an area of intense study.
It is not clear whether different SH2 domains carry sufficient information to specify the particular binding-site-specificity of the whole protein. From the studies described here, the recombinant p85 subunits seem to show very limited specificity in terms of the tyrosine-phosphorylated peptide sequences that they can recognize. A binding-site consensus for the Ptdlns 3-kinase of E/D E/D E/D E/D E/D Y M/V P M X X has recently been proposed ( Fig. 9b ; Cantley et al., 1991) . Our purified active enzyme, composed of p85a complexed with the 110 kDa subunit, appears to exhibit an absolute specificity of binding to phosphopeptides containing a YXXM motif within their sequence where the tyrosine is phosphorylated. All ofthese peptides conform to this proposed consensus, although our data would indicate that the residues between the absolutely conserved tyrosine and the methionine residues can be more varied than was originally suggested (see Fig. 9b ). Whether the conserved acidic residues are important for SH2-domain binding, or simply are required for tyrosine phosphorylation as part of the phosphorylation-site recognition motif for a kinase (Kemp & Pearson, 1990 ), remains to be established.
A specificity of binding of the Ptdlns 3-kinase complex has also been previously observed with respect to receptor binding, with the active Ptdlns 3-kinase complex binding to the PDGF receptor but not to the EDG receptor, whereas the expressed 85 kDa subunits were observed to bind indiscriminately to both receptors (Otsu et al., 1991) . The human PDGF fl-receptor contains two YXXM motifs close together within the kinase insert region. These are the sequences surrounding tyrosine-740 and tyrosine-75 1, both of which we demonstrate here can bind the bovine brain Ptdlns 3-kinase when phosphorylated. Escobedo et al. (199la) have demonstrated that a phosphopeptide containing both of these residues from the murine PDGF ,-receptor (where the two equivalent tyrosines to Y740 and Y751 are residues 708 and 719 respectively) can block binding of the Ptdlns 3-kinase from NIH 3T3 cells to the murine PDGF ,-receptor when either of these residues alone, or both together, are phosphorylated. A role in vivo for Y751 in binding of the PtdIns 3-kinase has been demonstrated by mutation of this residue to phenylalanine, which dramatically decreases Ptdlns 3-kinase binding to the activated receptor (Kazlauskas & Cooper, 1989 . Whether Y740 is a phosphorylation site in vivo remains to be demonstrated. The unphosphorylated peptide, as we observe here, is unable to block binding. Unlike the PDGF fl-receptor, the EGF-receptor cytoplasmic domain lacks a kinase insert region, but contains a single YXXM motif located within domain XI of the protein-tyrosine kinase domain (Hanks, 1991) . The Y1313 peptide used in this study is from the analogous region of the protein-tyrosine kinase domain of the hepatocyte growthfactor receptor (c-Met) and when phosphorylated is able to bind the bovine brain Ptdlns 3-kinase. However, although the Y1313 phosphopeptide is able to bind the Ptdlns 3-kinase in vitro, it is not known whether these residues are phosphorylated in vivo or whether this site would be available to bind SH2-containing proteins. Studies to determine whether this sequence is important for the observed binding in vivo of the Ptdlns 3-kinase to the hepatocyte growth factor receptor as demonstrated by Graziani et al. (1991) are needed. The differences observed between the phosphopeptide-sequence binding range of p85 and the active Ptdlns 3-kinase complex possibly suggest that when the 110 kDa protein is complexed with the p85a protein it can modulate the binding of the SH2 domain(s) for particular target sequences by altering either the affinity or its sequence specificity. It will be interesting to determine whether isolated bacterially expressed SH2 domains also show a decreased specificity in terms of the tyrosine-phosphorylated sequences to which they will bind.
The structural basis of the interaction between p85 and the 110 kDa protein in the complex remains to be established. Once it was immobilized on an appropriate phosphopeptide column, we were unable to separate the 110 kDa protein from the bound 85 kDa component. Similar findings have been reported by for Ptdlns 3-kinase purified from rat liver; they were unable to find any native conditions for separating the 85 kDa protein from the 110 kDa protein. As p85 possesses two SH2 domains, it is possible that one of these domains is involved in receptor interactions while the second mediates the interaction between the 110 and 85 kDa subunits. However, since no significant amounts of tyrosine-phosphorylated 110 kDa protein can be detected by Western blotting with anti-phosphotyrosine antibodies, it is unlikely that this occurs due to the interaction of the p85 SH2 domain with a tyrosine-phosphorylated sequence on p1 10. A recent report has demonstrated the ability of the SH2 domain of the c-abl protein to bind to a region of the Bcr-Abl fusion protein, which is only serine-and threoninephosphorylated (Pendergast et al., 1991) , suggesting that the SH2 domains may have a wider binding range than previously suspected and may also regulate the formation of complexes with serine-and threonine-phosphorylated proteins. The possibility exists therefore of an SH2-phosphoserine/phosphothreonine interaction mediating the formation of the p85/p1 10 active Ptdlns 3-kinase complex. Studies into the nature of this interaction will be facilitated by the availability of cloned expressed 110 kDa protein.
In summary, the use of the phosphopeptide affinity techniques described have resulted in highly purified Ptdlns 3-kinase, although not in soluble form, and they have greatly increased the use of the purified material for many types of study. The immobilized enzyme is fully active and has been used both for kinetic studies and for the generation of large quantities of 3-phosphorylated phosphoinositides. The techniques described here have allowed the isolation of microgram amounts of the 110 kDa protein associated with p85, resulting in the generation of over 200 amino acids of peptide sequence data from 16 distinct lysyl-endopeptidase proteolytic fragments of p1 10. cDNA clones for this putative catalytic domain of the Ptdlns 3-kinase from bovine cDNA libraries have been isolated for examination of their ability to encode an active catalytic subunit of the Ptdlns 3-kinase. In addition, the phosphopeptide columns described in this paper have allowed the further analysis of SH2 domain binding specificity. It will be interesting to determine association and dissociation constants with respect to several phosphopeptides in order to elucidate the different affinities of both whole SH2-domain-containing proteins (including both p85 proteins, PLCy, src-family kinases and GAP), and isolated expressed SH2 domains from these proteins.
